1143-70-0
基本信息
3,8-二羥基-6H-苯并[C]色烯-6-酮
3,8-二羥基-6H-苯并[C]苯并吡喃-6-酮
3,8-二羥基-6H-二苯并(二,四)吡喃-6-酮
3,8-二羥基-6H-二苯并[B,D]吡喃-6-酮
T24和CACO-2細胞抑制劑(UROLITHIN A)
urolithin-A(UA
JACS-1143-70-0
Castoreum pigment I
3,8-Dihydroxyurolithin
3,8-Hydroxydibenzo-alpha-pyrone
2',7-Dihydroxy-3,4-benzocoumarin
3,8-dihydroxy-6H-dibenzopyran-6-one)
3,8-DIHYDROXYDIBENZO-(B,D)PYRAN-6-ONE
3, 8-Dihydroxy-6H-benzo[c]chromen-6-one
物理化學性質(zhì)
常見問題列表
Human Endogenous Metabolite
|
Micromolar urolithin A concentrations induces both autophagy and apoptosis. Urolithin A suppresses cell cycle progression and inhibited DNA synthesis in human sw620 colorectal cancer cells.
Urolithin A shows antiproliferative effects and inhibits T24 and Caco-2 cell growth with IC
50
s of 43.9 and 49 μM, respectively.
Urolithin A exerts a dose- and time-dependent significant arrest at G2/M and S phases after treatments with 50 and 100 μM at 24 and 48 h compared to control cells. It induces cell apoptosis with 50 and 100 μM .
Urolithin A shows potent antiproliferative activity on HepG2 cells. When cell death is induced by Urolithin A, the expression of β-catenin, c-Myc and Cyclin D1 are decreased and TCF/LEF transcriptional activation is notably down-regulated. Urolithin A also increases protein expression of p53, p38-MAPK and caspase-3, but suppresses expression of NF-κB p65 and other inflammatory mediators.
The volume of paw edema is reduced at 1 h after oral administration of urolithin A. In addition, plasma in treated mice exhibited significant oxygen radical antioxidant capacity (ORAC) scores with high plasma levels of the unconjugated form at 1 h after oral administration of urolithin A.